Concord Biotech Limited expects financial year 2027 growth to exceed its historical rate of 18%, supported by normalized operations and new business verticals. The company reported a 30% decline in consolidated net profit for FY26 to ₹260 crore, down from ₹371.6 crore in FY25, citing geopolitical headwinds, supply chain disruptions, and deferred tenders. Consolidated revenue from operations fell 12% to ₹1,054.9 crore from ₹1,200.1 crore in the previous year. For the quarter ended March 31, 2026, net profit stood at ₹88.5 crore on revenue of ₹326.1 crore.

Financial Context

The decline in profitability was attributed to industry headwinds, including slowed procurement activities in the U.S. during the first half of the year and restricted supplies to Europe for nearly three months due to approval delays. A major tender in the Middle East remained in abeyance, impacting revenues by approximately ₹25 crore. Despite these challenges, the company maintained a zero-debt status with cash and cash equivalents of ₹414 crore as on March 31, 2026.

Operational Highlights

Management highlighted that FY26 challenges were temporary rather than structural, with conditions improving in the second half. The company strengthened its regulatory filings, completing inspections by U.S. FDA, EU GMP, and WHO-GMP. The injectable facility commenced operations and received WHO-GMP certification, positioning it for domestic and government supply contracts. Additionally, the company commenced supplies to two innovator companies and commercialized Fusidic Acid.

Future Outlook

Looking ahead, the company anticipates operating leverage from its injectable facility and U.S. subsidiary, Stellon Biotech, with expenses for these units fully booked in FY26. Management expects a 1% to 1.5% positive impact on EBITDA from renewable energy savings. Capacity utilization stood at 77% for Unit 1, 30% for Unit 2, and 53% for Unit 3, with total manufacturing capacities supporting a peak revenue potential of approximately ₹3,000 crore.

Key Financial Metrics

Segment Performance

Revenue from the API segment stood at ₹828.8 crore for FY26, while the formulation segment contributed ₹226.1 crore. Geographically, domestic revenue was ₹563.6 crore, and exports revenue was ₹491.3 crore. The Board of Directors has recommended a final dividend of ₹7.55 per equity share for FY26, with July 24, 2026, fixed as the record date.

Concord Biotech has secured approval from the U.S. Food and Drug Administration (USFDA) for its Mycophenolate Mofetil Oral Suspension ANDA, opening access to an approximately $30 million market opportunity in the United States. This regulatory clearance represents a notable addition to the company's growing portfolio of U.S.-approved pharmaceutical products.

Regulatory Approval Details

The USFDA approval for Mycophenolate Mofetil Oral Suspension underscores Concord Biotech's continued focus on expanding its presence in the U.S. generics market. Mycophenolate Mofetil is widely used as an immunosuppressant, particularly in organ transplant patients, making it a therapeutically significant product.

Market Opportunity

With the USFDA nod in place, Concord Biotech is positioned to address an approximately $30 million addressable market in the United States for this product. The approval strengthens the company's U.S. generics pipeline and reflects its ongoing commitment to regulatory compliance and product development in high-value therapeutic segments.